Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0KL4J
|
|||
| Former ID |
DAP000727
|
|||
| Drug Name |
Rabeprazole
|
|||
| Synonyms |
Dexrabeprazole; Eraloc; Rebeprazole sodium; CL23619; LY307640; Aciphex (TN); Eraloc (TN); Pariet (TN); Rabeprazole (INN); Rabeprazole [BAN:INN]; Rabeprazole [INN:BAN]; Rablet (TN); 2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole; 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole; 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Approved | [1], [2] | |
| Therapeutic Class |
Antiulcer Agents
|
|||
| Company |
Eisai; Johnson & Johnson
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H21N3O3S
|
|||
| Canonical SMILES |
CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC
|
|||
| InChI |
1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)
|
|||
| InChIKey |
YREYEVIYCVEVJK-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 117976-89-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10066, 5392621, 7980480, 8153096, 14828218, 29224100, 46386636, 46506366, 49681560, 49742702, 50064224, 50769860, 57288826, 57322572, 85174502, 92308674, 93166177, 96025149, 103370406, 104029616, 104308073, 118212884, 124659135, 125338815, 126525321, 126591137, 126655846, 126670688, 126670689, 129836330, 131295768, 134338014, 135040318, 137018746, 142316515, 142318546, 142519546, 152034678, 160825170, 160964463, 162022428, 163092473, 163384417, 164339280, 164787748, 166650031, 170500544, 172080531, 178103864, 179116873
|
|||
| ChEBI ID |
CHEBI:8768
|
|||
| ADReCS Drug ID | BADD_D01898 ; BADD_D01899 | |||
| SuperDrug ATC ID |
A02BC04
|
|||
| SuperDrug CAS ID |
cas=117976893
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia obeum
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Blautia obeum was decreased by Rabeprazole Sodium salt (adjusted p-values: 1.53E-06). | |||
|
Studied Microbe: Dorea formicigenerans
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Dorea formicigenerans was decreased by Rabeprazole Sodium salt (adjusted p-values: 5.06E-06). | |||
|
Studied Microbe: Eubacterium rectale
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium rectale was decreased by Rabeprazole Sodium salt (adjusted p-values: 1.84E-03). | |||
|
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia intestinalis was decreased by Rabeprazole Sodium salt (adjusted p-values: 8.54E-04). | |||
|
Studied Microbe: Ruminococcus bromii
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus bromii was decreased by Rabeprazole Sodium salt (adjusted p-values: 1.69E-03). | |||
|
Studied Microbe: Ruminococcus torques
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus torques was decreased by Rabeprazole Sodium salt (adjusted p-values: 1.36E-05). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Gastric H(+)/K(+) ATPase alpha (ATP4A) | Target Info | Inhibitor | [4], [5] |
| KEGG Pathway | Oxidative phosphorylation | |||
| Collecting duct acid secretion | ||||
| Gastric acid secretion | ||||
| Pathwhiz Pathway | Gastric Acid Production | |||
| Reactome | Ion transport by P-type ATPases | |||
| WikiPathways | Iron uptake and transport | |||
| Secretion of Hydrochloric Acid in Parietal Cells | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7290). | |||
| REF 2 | An overview of proton pump inhibitors. Gastroenterol Nurs. 2003 Sep-Oct;26(5):182-90. | |||
| REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 4 | Review article: rabeprazole's tolerability profile in clinical trials. Aliment Pharmacol Ther. 1999 Oct;13 Suppl 5:17-23. | |||
| REF 5 | Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy. Aliment Pharmacol Ther. 1999 Oct;13 Suppl 5:11-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.